Leading the market with 9 clinical studies

Cerebiome® is the most documented psychobiotic with 9 clinical studies among which the first-ever human clinical study involving healthy stressed adults and probiotic intake.

Pioneering clinical studies on a healthy population

Diop 2008: The first study demonstrating the effect of a probiotic on stress-induced gastrointestinal symptoms

75 healthy volunteers (18-60 years old) with at least 2 symptoms of stress were enrolled to take Cerebiome® or placebo for 3 weeks. The study showed a significant reduction of stress-induced gastrointestinal symptoms as assessed by 62 criteria.

Messaoudi 2010: The first study that demonstrated the positive impact of a probiotic on occasional stress in healthy humans.

This gold-standard study (randomized, placebo-controlled, and double-blind), was conducted on 55 healthy volunteers (30 – 60 years old) for the intake of Cerebiome® or placebo.

After 30 days of intake, a significant reduction of psychological stress as assessed by HSCL-90 tests (validated questionnaire) was shown in the Cerebiome® group. These results were correlated to the significant decrease of cortisol, a biomarker of stress. In less stressed subjects, significant improvement of PSS score, HADS scores, and anxiety/depression score in HSCL were demonstrated in a post-hoc study [Messaoudi 2011].

Wiacek 2024: Trend toward improvement in sleep quality according to validated PSQI questionnaire

It has been demonstrated that stress could have a significant impact on sleep quality. In 2024, Wiacek et al. conducted a randomized double blind pilot clinical study in 15 healthy dancers who tend to have psychological and physical stress. They took either Cerebiome® or placebo for 12 weeks. The results demonstrated a trend toward an improvement of sleep quality according to PSQI validated questionnaire.

First clinical study on gut-brain-skin axis

Kassem 2025: First significant data on stress-related skin conditions, in healthy adults

An open-label study evaluated the effect of Cerebiome® on stress and skin health in young French women. After 8-week oral Cerebiome® supplementation, the results showed significant improvement in perceived stress level, sleep quality and skin health which were evaluated by validated questionnaires and under the supervision of a dermatologist. Through the self-evaluation questionnaire, 91% of women reported to be satisfied with the global performance of Cerebiome®. The data supported benefits of Cerebiome® in holistic wellbeing.

• Improvement in perceived stress

• Improvement in skin appearance

• Improvement in sleep quality

Significant improvement in the overall proportion of women who were able to fall asleep or stay asleep during bedtime^a.

Significant reduction in the total proportion of women having difficulty staying awake during their normal waking hours^b.

a: “How often do you have trouble going to sleep or staying asleep?” Combining “Rarely” and “Never” answers.
b: “How often do you find it difficult to stay awake during your normal waking hours when you want to?” Combining “All of the time”,“Most of the time” and “Sometimes” answers.
*p < 0.05 **p < 0.01

Pioneering clinical studies on depressed participants

Rominj 2017: Depressed participants without ongoing treatment

This was the first study conducted with Cerebiome® on depressed participants. This gold-standard study demonstrated that Cerebiome® significantly decreased dry mouth and sleep disruption (p<0.05) compared to the placebo group.

Kazemi 2018: Depressed participants with ongoing treatment (for at least 3 months)

This randomized, double-blind, and placebo-controlled study included 110 patients suffering from mild to moderate depression that were receiving antidepressant treatment.

The probiotic was used as an adjunct therapy to conventional antidepressant treatment and showed a significant decrease in Beck Depression Inventory (BDI) scores, from 18 down to 9 on average. These results are clinically significant, showing that the patients, after treatment with Cerebiome®, were now categorized with “minimal depression” according to the validated assessment scale. Additionally, the Cerebiome® group showed a decrease in the blood kynurenine/tryptophan ratio, which suggests that tryptophan was diverted toward the synthesis of serotonin and away from the inflammatory pathway (p<0.05).

Wallace 2021: Depressive participants – treatment naïve

An open-label study by Wallace and Milev found that in treatment-naïve patients, Cerebiome® had a positive effect on mood, anxiety, anhedonia, sleep quality and perceived stress, lasting up to eight weeks after psychobiotic intake.